In the majority of irresectable stage IIIc or metastatic BRAFV600 positive melanoma patients treated with combined BRAF/MEK inhibitors, metabolic alterations occur rapid after the initiation of therapy. The gene discussed is MAP2K7; the disease is melanoma.